Fewer medical centers ordering its Proxcelan seeds led to a dip in sales revenue for medical isotope developer IsoRay in its 2009 fiscal second quarter (end-December 31, 2008).
The Richland, WA-based medical isotope developer posted revenue of $1.3 million, down 25% from the $1.7 million reported in the second quarter of fiscal 2008. The company was able to reduce its net loss, however, improving from last year's second quarter loss of $2.8 million to a loss of $1.6 million in the 2009 fiscal second quarter.
Related Reading
IsoRay taps VP, November 24, 2008
Physician vacations affect IsoRay revenue in Q1, November 13, 2008
IsoRay's sales grow in fiscal 2008, August 20, 2008
IsoRay authorizes stock repurchase plan, June 3, 2008
IsoRay posts sales increase, net loss in Q3, May 14, 2008
Copyright © 2009 AuntMinnie.com
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
